RxDoctor Payments Data

James Colvard, DO

Family Medicine · Vestavia Hills, ALNPI 1225312432

Payments from drug & device makers

$1,260in general payments, 2019–2025

Across 55 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$289
  • Novo Nordisk$210
  • Johnson & Johnson$151
  • Boston Scientific$126
  • GSK$124
  • Pfizer$103
  • plus $258 from 8 others

What the payments were for

  • Food & beverage$1,260100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,260 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$81,060
Medicare patients
272
Services billed
945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$93,697
OzempicSemaglutide68$77,715
EliquisApixaban81$69,562
JanuviaSitagliptin Phosphate52$65,587
MounjaroTirzepatide61$62,980
TradjentaLinagliptin35$33,950
XareltoRivaroxaban40$32,663
RybelsusSemaglutide24$27,063
FarxigaDapagliflozin Propanediol17$22,513
TrulicityDulaglutide21$21,631
LinzessLinaclotide22$18,545
Breo ElliptaFluticasone/Vilanterol30$16,741
MyrbetriqMirabegron23$14,040
Atorvastatin Calcium785$12,190
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$19$127,647111 claims
Novo NordiskOzempic, Rybelsus$210$104,77892 claims
PfizerEliquis$103$69,56281 claims
Johnson & JohnsonXarelto$151$32,66340 claims
AbbVieLinzess, Synthroid$289$23,964105 claims
GSKBreo Ellipta$124$16,74130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Vestavia Hills

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →